The recent surge in publicity-and stock price-surrounding Cytogen has been accompanied by a private stock placement that has stuffed the Princeton, NJ-based company's coffers with $10 million. Investors picked up an aggregate of 1,172,332 shares of
The recent surge in publicity-and stock price-surrounding Cytogen has been accompanied by a private stock placement that has stuffed the Princeton, NJ-based company's coffers with $10 million. Investors picked up an aggregate of 1,172,332 shares of common stock at $8.53 per share. They will also receive warrants to purchase an aggregate of the same number of shares of common stock at an exercise price of $12.80 per share. Cytogen executives plan to use the proceeds to reacquire North American and Latin American marketing rights for the company's radiopharmaceutical, Quadramet.
New MRI Research Explores Links Between Waist-to-Hip Ratio and Memory in Aging
March 13th 2025Researchers found that a higher waist-to-hip ratio in midlife was associated with higher mean diffusivity in 26 percent of total white matter tracts in the cingulum as well as the superior and inferior longitudinal fasciculus.
Can Ultrasound-Based Radiomics Enhance Differentiation of HER2 Breast Cancer?
March 11th 2025Multicenter research revealed that a combined model of clinical factors and ultrasound-based radiomics exhibited greater than a 23 percent higher per patient-level accuracy rate for identifying HER2 breast cancer than a clinical model.